RESUMEN
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic lung disease caused by the sensitization of Aspergillus fumigatus. In recent years, the research into ABPA has progressed, the testing methods have improved and the diagnostic criteria have been continuously updated. There is no gold standard for the diagnosis of the disease. The diagnostic criteria for ABPA include predisposing diseases, fungal-related immunoassay and pathological examination. Understanding the clinical significance of ABPA diagnostic criteria may help to prevent irreversible bronchopulmonary injury, improve respiratory function and improve the prognosis of patients.
Asunto(s)
Aspergilosis Broncopulmonar Alérgica , Humanos , Aspergilosis Broncopulmonar Alérgica/diagnóstico , Inmunoglobulina E , Aspergillus fumigatus , Pulmón , BronquiosRESUMEN
MicroRNAs (miRNAs) are differentially expressed in various cancers and act as oncogenes or tumor suppressors. MiR-383 has been characterized as a cancer suppressor in several cancers. However, the exact expression patterns of miR-383 and the precise molecular mechanisms underlying its role in ovarian cancer have not been investigated thoroughly. In this study, we found that the expression of miR-383 was significantly downregulated in ovarian cancer tissues and ovarian cancer cell lines. Ectopic expression of miR-383 remarkably suppressed the ovarian cancer cell proliferation by enhancing cell apoptosis and significantly inhibited the invasion of ovarian cancer cells, while low expression of miR-383 exhibited the opposite effect. Bioinformatics analysis suggested LDHA as a novel target of miR-383, and miR-383 suppressed the expression level of LDHA mRNA by direct binding to its 3'-untranslated region (3'UTR). Expression of miR-383 was negatively correlated with LDHA in ovarian cancer tissues. In addition, modulation of miR-383 expression could affect the aerobic glycolysis in the ovarian cancer cells. Furthermore, Silencing of LDHA counteracted the effects of miR-383 suppression, while its overexpression reversed tumor inhibitory effects of miR-383. In conclusion, our study demonstrated that miR-383 regulated LDHA expression in ovarian cancer cells, thereby stunting glycolysis, cell proliferation and invasion.
Asunto(s)
Glucólisis , L-Lactato Deshidrogenasa/metabolismo , MicroARNs/genética , Neoplasias Ováricas/patología , Regiones no Traducidas 3' , Apoptosis , Línea Celular Tumoral , Proliferación Celular , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , L-Lactato Deshidrogenasa/genética , Neoplasias Ováricas/genéticaRESUMEN
The activity of total thymidine kinase in serum (S-TK) has been used as a tumor maker for decades. To date such activity has been determined using [125]I-iodo-deoxyuridine as a substrate. The aim of this study was to develop a new, antibody-based technique for the measurement of cytoplasmic thymidine kinase (TK1) in serum. Both mono- and polyclonal antibodies against S-TK1 were used in dot blot assay. S-TK1 was characterized by SDS and IEF techniques. Sixty-five breast cancer patients were studied, including 17 preoperative and 38 postoperative tumor-free patients and 10 patients with metastases to the lymph nodes (N1-2). They were compared to patients with benign tumors (n=21) and healthy volunteers (n=11). S-TK1 was low (0-1.0 pM) in healthy volunteers, while in preoperative patients the level was increased 6-110-fold. Significant differences were observed between preoperative patients and healthy volunteers (p=0.005), preoperative patients and patients with benign tumors (p<0.001), and preoperative patients and postoperative patients without metastases (p<0.001). No significant difference was observed between preoperative patients and postoperative patients with metastases (p=0.191). The S-TK activity in preoperative patients was also high in serum, but no decrease was observed following surgery. In conclusion, the anti-TK1 antibody could be a good marker for monitoring the response of breast cancer patients to therapy.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Anticuerpos Antineoplásicos/inmunología , Biomarcadores de Tumor/sangre , Neoplasias de la Mama/enzimología , Immunoblotting , Isoenzimas/sangre , Proteínas de Neoplasias/sangre , Timidina Quinasa/sangre , Secuencia de Aminoácidos , Biomarcadores de Tumor/inmunología , Electroforesis de las Proteínas Sanguíneas , Western Blotting , Neoplasias de la Mama/sangre , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Método Doble Ciego , Femenino , Células HeLa , Humanos , Focalización Isoeléctrica , Isoenzimas/inmunología , Metástasis Linfática , Datos de Secuencia Molecular , Proteínas de Neoplasias/inmunología , Periodo Posoperatorio , Reproducibilidad de los Resultados , Timidina Quinasa/inmunologíaRESUMEN
Evolutionary graphs (EGs) were initially introduced in 2005 and give an outlet for the evolutionary dynamic determined by the population structures, the fitness of the mutants and the number of the individuals. Bi-level EGs with different fitness are discussed. The corresponding fixation probability is given, especially when the lower level and the upper level are all isothermal. The optimisation fixation probabilities are also built if the lower and the upper graphs are all isothermal structures and the number of the total individuals is finite. At last, some applications to the system biology are involved.